Leishmaniasis Treatment Market Size, Share, Growth, Trends and Industry Analysis, By Type (Meglumine Antimoniate, Pentamidine, Hydroxyl Amidine Stilbene, Amphotericin B), By Application (Visceral Leishmaniasis, Cutaneous Leishmaniasis), Regional Insights and Forecast From 2025 to 2034

• 

  Request a Free sample to learn more about this report

LEISHMANIASIS TREATMENT MARKET OVERVIEW

The global leishmaniasis treatment market size is predicted to reach USD 0.39 billion by 2034 from USD 0.16 billion in 2025, registering a CAGR of 10.58% during the forecast period from 2025 to 2034.

The United States Leishmaniasis Treatment market size is projected at USD 0.05 billion in 2025, the Europe Leishmaniasis Treatment market size is projected at USD 0.04 billion in 2025, and the China Leishmaniasis Treatment market size is projected at USD 0.06 billion in 2025.

Cutaneous leishmaniasis is an infection caused by a parasite. It is carried by the female sandfly, which may be found in both the new and ancient worlds. Fluconazole, tablet azole antifungals-systemic, Diflucan, impavido, miltefosine capsule, pentam 300 solution, reconstituted, off, and pentamidine 300 mg solution for injection antiprotozoal agents are among the drugs approved for the treatment of cutaneous leishmaniasis.

Cutaneous Leishmaniasis is not fatal, but it can have a catastrophic impact on local populations. Cutaneous Leishmaniasis-caused disfiguring lesions can lead to stigmatisation, ostracism, reduced schooling, and economic loss, especially in populations with already inadequate resources. It can spread and cause generalised severe illnesses in immunocompromised people. The incidence of leishmaniasis is heavily influenced by environmental and natural variables. Factors such as vegetation and climate have a significant effect in the multiplication and growth of sandflies, as well as the following epidemic of leishmaniasis.

KEY FINDINGS

COVID-19 IMPACT

Lockdown Distorts the market due to the Decrease in Demand of the Treatment

The global COVID-19 pandemic has been unprecedented and staggering, with leishmaniasis treatment market experiencing Higher-than-anticipated demand across all regions compared to pre-pandemic levels. The sudden rise in CAGR is attributable to the market's growth and demand returning to pre-pandemic levels once the pandemic is over.

COVID-19 has created an unprecedented worldwide public health disaster that has damaged nearly every industry. Its long-term consequences are projected to have an impact on industry growth throughout the predicted period. The COVID-19 outbreak had a negative impact on the global economy and hampered the growth of the leishmaniasis treatment market because there was a drop in demand for leishmaniasis treatment as a result of millions of COVID-19 positive patients in healthcare facilities around the world. Because of the availability of many treatment options in the post-pandemic period, the market is likely to grow. Furthermore, the epidemic has a non-favourable influence on the enterprise's business operations, which distorts the market as a whole. This has had an effect on the industry.

LATEST TRENDS

Advancements Of New Chemical Drugs To Stimulate Market Expansion

In 2016, the Drugs for Neglected Diseases initiative (DNDi') found two novel chemical entities (NCE) DNDI-6148 and DNDI-0690 that are in the preclinical research stage for the cutaneous leishmaniasis treatment. CpG-D35, an immunomodulator, is also under pre-clinical research and will be used in conjunction with medication treatment to combat cutaneous leishmaniasis. These new developments will soon translate medication development into novel treatment therapies, supporting the growth of the leishmaniasis industry. Thus, the process of developing new advancements of new chemical drugs is a major trend that is creating opportunity for the industry to flourish. The market's overall expansion is primarily the result of these recent changes.

• According to the World Health Organization (WHO), more than 90% of new cases of visceral leishmaniasis in 2023 were reported in 7 countries, including Brazil, Ethiopia, India, Kenya, Somalia, South Sudan, and Sudan, spurring multi-regional drug development efforts.

• As per India’s National Vector Borne Disease Control Programme (NVBDCP), the country reduced kala-azar cases from 44,533 in 2007 to 520 in 2023, largely through combination therapies and early diagnosis campaigns involving leishmaniasis-specific treatments.

Request a Free sample to learn more about this report

LEISHMANIASIS TREATMENT MARKET SEGMENTATION

By Type

The market is divided into categories based on type, Meglumine Antimoniate, Pentamidine, Hydroxyl Amidine Stilbene, Amphotericin B and others.

By Application

The market is divided into Visceral Leishmaniasis, Cutaneous Leishmaniasis and other categories based on application.

DRIVING FACTORS

Increasing Awareness Regarding Healthcare That Boosts The Market

The leishmaniasis treatment market is predicted to expand due to rising healthcare spending. According to the WHO, "health spending is growing faster than the rest of the global economy, accounting for 10% of global GDP." This increased trend in global health spending may be observed more clearly in low- and middle-income nations, where health spending is expanding faster than in high-income ones. Factors such as emerging market expansion, ageing and expanding populations, breakthroughs in medical treatments, urbanisation, and rising labour expenses can all be contributed to this. Consequently, during the predicted period, increased product dependence will support industry growth. As a result, the market will benefit from growth and increasing awareness regarding healthcare. It will help the Healthcare sector flourish and accelerate the leishmaniasis treatment market growth.

Rising In The Pathological Tests To Support Market Expansion

Several pathology tests aid in the diagnosis of the medical condition. Because of increased demand for pathological testing for the diagnosis of several infectious illnesses, serological tests dominated the market. As the standard test for reliable illness diagnosis, parasitological assessment is expected to rise significantly.  This stimulates market growth. Together, these elements are encouraging market expansion, which is raising business revenues. As a result, the market will grow thanks to the growing Pathological tests.

• According to the Drugs for Neglected Diseases initiative (DNDi), over 2.3 million people globally remain at risk of contracting visceral leishmaniasis due to poverty, malnutrition, and poor housing, driving the development and distribution of affordable treatment options.

• As per the World Bank, over 1 billion people live in areas endemic to neglected tropical diseases (NTDs) including leishmaniasis, encouraging collaborative health programs and increased procurement of antiparasitic treatments.

RESTRAINING FACTOR

Supply Chain Barriers And High Cost Will Prevent Market Expansion

The potential for the Cutaneous leishmaniasis treatment market is limited due to high entry hurdles, since the market's scope is limited to particular nations or areas. Addressing supply chain constraints in Eastern Africa necessitated persistent and targeted actions such as pooled buying, enhanced forecasting, and more commitment and resources. The cost of treating Leishmaniasis is quite high due to the high cost of the medications. Aside from that, the medications used in therapy might have serious side effects. Although new treatment alternatives are being developed, it is expected to provide a wide range of therapeutic measures against these disorders while reducing adverse effects. This is a significant impediment to the market. This will be a significant impediment to market growth during the forecast period. This could be a significant issue limiting market growth. If this issue is resolved, the market will immediately begin to grow.

• According to WHO data, post-kala-azar dermal leishmaniasis (PKDL) develops in 10–20% of treated visceral leishmaniasis cases, necessitating long-term and expensive follow-up treatments that limit healthcare access in resource-limited settings.

• As per Médecins Sans Frontières (MSF), treatment regimens for leishmaniasis often require up to 30 days of daily injections, creating compliance and logistical challenges in rural or conflict-prone regions.

• Request a Free sample to learn more about this report

•  

LEISHMANIASIS TREATMENT MARKET REGIONAL INSIGHTS

North America to Lead the Market owing to Rapid Urbanization

Since this area is the largest user of the product, the market for Leishmaniasis Treatment in North America has profited from the region's expanding industrial development and several driving factors that have boosted the potential sectors. The increasing demand for products in the visceral leishmaniasis, cutaneous leishmaniasis and other industries is one of the important factors driving the leishmaniasis treatment market share. Rapid urbanisation trends will further strengthen the market as a whole.

KEY INDUSTRY PLAYERS

Leading Manufacturers To Boost Product Demand

The analysis covers data on market participants and their positions within the industry. Through appropriate research, mergers, technological development, expanding production facilities, and collaboration, data is being gathered and made available. Information on manufacturers, regions, types, applications, sales channels, distributors, traders, dealers, research findings, and more is provided in the study on materials.

• Pieris Pharmaceuticals: According to company reports, Pieris Pharmaceuticals invested in over 5 pipeline biologics programs in 2023 focused on infectious diseases, including pre-clinical assets targeting leishmania antigens for immunotherapy innovation.

• Eurofins Advinus: As per India’s Central Drugs Standard Control Organization (CDSCO), Eurofins Advinus participated in more than 15 regulatory toxicology studies for anti-leishmanial compounds in 2023, supporting global preclinical drug approval efforts.

List of Top Leishmaniasis Treatment Companies

• Merck (U.S.)
• iCo Therapeutics (Canada)
• AEterna Zentaris (U.S.)
• AEterna Zentaris AG (U.S.)
• Eurofins Advinus (India)
• Pieris Pharmaceuticals (U.S.)

REPORT COVERAGE

The study goes into great detail about market segmentation by type and application. The study examines a broad range of participants, including existing and potential market leaders. A considerable market expansion is anticipated as a result of several important factors. In order to provide market insights, the research additionally analyses elements that are probably to boost Leishmaniasis treatment Market. The report makes forecasts for market expansion during the projected time period. The objective of the regional study is to explain why one region dominates the worldwide market. There are a lot of issues that have all been carefully considered that prevent the industry from growing. The research also contains a market strategic analysis. It includes thorough market information.